Full-Time

Research Associate

Molecular Development

UntilLabs

UntilLabs

51-200 employees

Advances reversible organ cryopreservation technology

Compensation Overview

$90k - $100k/yr

California, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Data Analysis
Requirements
  • You have an undergraduate and/or master’s degree in Bioengineering, Molecular Biology, Biochemistry, Neuroscience, Immunology, or a related field.
  • 2+ years of experience in a similar role and a record of success performing complex laboratory procedures. Prior industry experience is preferred.
  • You have a good understanding of cryopreservation (vitrification, cryoprotectants, ice nucleation/growth).
  • You demonstrate an ability to work in a multidisciplinary lab environment and rapidly learn new skills in other fields. Prior exposure to interdisciplinary projects bridging biology and engineering is strongly preferred.
  • You have experience independently maintaining and working with mammalian cell lines. Prior experience with 3D in vitro models is strongly preferred.
  • You demonstrate agency, problem solving, passion for discovery, and a drive to push the boundaries of science through meaningful involvement in an ambitious project.
Responsibilities
  • Execute high-throughput screening (HTS) assays to support a molecular discovery pipeline, utilizing automated liquid handlers.
  • Perform microplate-based assays (fluorescence, luminescence, absorbance), microscopy, and genomics (qPCR, RNA-seq) experiments to support the molecular discovery pipeline.
  • Maintain and experiment with various mammalian cell-based in vitro models (immortalized, primary and stem cells).
  • Collaborate closely with cross-functional teams to translate experimental findings into practical solutions.
  • Ensure meticulous, accurate, and timely experimental collection, data analysis, and data reporting/presentation.

UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

San Francisco, California

Founded

2024

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $58M Series A in September 2025 from Founders Fund, Lux Capital, Field Ventures.
  • Enables organ banking, better matching, reduces waitlist deaths from time constraints.
  • Foundational for whole-body preservation, backed by over $100M funding.

What critics are saying

  • FDA lacks approval framework, delaying commercialization 3-5 years.
  • Normothermic systems from OrganOx, Transmedics capture market pre-approval.
  • Cryoprotectant toxicity triggers rejection, forces redesign in 24-36 months.

What makes UntilLabs unique

  • Until Labs develops reversible cryopreservation for organs using vitrification without ice formation.
  • Engineers five dimensions: perfusion, cryoprotectants, cooling, rewarming, and post-thaw assays.
  • Progressed from neural slices to preclinical kidneys, hearts, lungs, livers.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at UntilLabs who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Flexible Work Hours

Paid Holidays

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Commuter Benefits

Professional Development Budget

Company News

Pioneer Publishers
Sep 22nd, 2025
Until Labs Secures $58M for Cryopreservation

Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.

Fenwick
Sep 22nd, 2025
Fenwick Represents Until Labs in $58M Series A Funding

Fenwick represents Until Labs in $58M Series A funding.